A comparative randomised controlled parallel group study of maternal, fetal and neonatal outcomes of labetalol versus methyldopa in the treatment of new onset hypertension during pregnancy

International Journal of Pharma and Bio Sciences

Volumn 3, Issue 1, 2012, Pages P201-P211

  Verma, Reena ^a   Lahon, Kingshuk ^a,b   Tonpay, S D ^c   Kale, Vrunda Joshi ^c  

^a LN Medical College ^*  (India)

^b MAHATMA GANDHI MEDICAL COLLEGE AND RESEARCH INSTITUTE   (India)

^c G R MEDICAL COLLEGE   (India)

Author keywords

Fetal; Hypertension; Labetalol; Maternal; Methyldopa; Pregnancy

Indexed keywords

ALBUMIN; CREATININE; LABETALOL; METHYLDOPA; UREA;

APGAR SCORE; ARTICLE; BIRTH WEIGHT; BRADYCARDIA; CESAREAN SECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; ECLAMPSIA; FEMALE; FETUS OUTCOME; GESTATIONAL AGE; HUMAN; HYPERTENSIVE CRISIS; HYPOGLYCEMIA; INDIA; LABOR INDUCTION; LABOR ONSET; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NEWBORN DEATH; NEWBORN INTENSIVE CARE; NEWBORN JAUNDICE; PARALLEL DESIGN; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STILLBIRTH; TEACHING HOSPITAL; THROMBOCYTE COUNT; UREA BLOOD LEVEL; VAGINAL DELIVERY;

EID: 84909633661     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Davey DA, MacGillivray I., The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol, 158(4):892-898, (1988).
2. Magee LA, von Dadelszen P., Treatment of hypertension in pregnancy. Can J Clin Pharmacol, 11(2):e199-e201, (2004).
3. Podymow T, August P, Update on the use of antihypertensive drugs in pregnancy. Hypertension, 51:960-969, (2008).
4. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ., Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev, (1): CD002252, DOI: 10.1002/14651858.CD002252.pub2, (2007).
5. Magee LA, Helewa M, Moutquin JM, von Dadelszen P., SOGC Clinical Practice Guideline: Diagnosis, evaluation and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can, 30(3):Suppl 1 S1-S48, 2008.
6. Cruickshank DJ, Robertson AA, Campbell DM, MacGillivray I., Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. Eur J Obstet Gynecol Reprod Biol, 45(1):47-51, (1992).
7. El-Qarmalawi AM, Morsy AH, Al-Fadly A, Obeid A, Hashem M., Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynecol Obstet, 49(2):125-130, (1995).
8. Magee LA, Duley L., Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev, (3): CD002863. PM:12917933, (2003).
9. Lamming GD, Broughton Pipkin F, Symonds ED., Comparison of the alpha and beta blocking drug, labetalol and methyldopa in the treatment of moderate and severe pregnancy-induced hypertension. Clin Exp Hypertens, 2(5):865-895, (1980).
10. JJ Walker, A Crooks, L Erwin and AA Calder. Labetalol in pregnancy induced hypertension. Fetal and maternal effects. In: Riley and Symmonds (eds.), The investigation of labetalol in the management of hypertension in pregnancy, Excerpta medica, Amsterdam, the Netherlands,1982, pp. 148-160
11. Mohapatra S, Pradhan BB, Satpathy UK, Mohanty A, Pattnaik JR, Platelet estimation: its prognostic value in pregnancy induced hypertension. Indian J Physiol Pharmacol, 51(2):160-164, (2007).
12. Rahim R, Nahar K, Khan IA., Platelet count in 100 cases of pregnancy induced hypertension. Mymensingh Med J,19(1):5-9, ((2010).
13. Lardoux H, Blazquez G, Leperlier E, Gerard J., Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol. Arch Mal Coeur Vaiss, 81:Spec No:137-140, (1988).
14. Mrozikiewicz AS, Drews K., Methyldopa in therapy of hypertension in pregnant women. Ginekol Pol, 75:160-165, (2004).
15. Redman CWG, Gallery ED, Mitchell MD., Fall in BP in response to volume expansion in pregnancy associated hypertension (PE): Why does it occur? BMJ, 2(2):177-182, (1984).
16. Pickles CJ, Symonds EM, Pipkin FB., The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol, 96:38-43, (1989).
17. Plouin PF, Breart G, Maillard F, Papiernik E, Relier JP., Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. Br J Obstet Gynaecol, 95:868-876, (1988).
18. Munshi UK, Deorari AK, Paul VK, Singh M., Effects of maternal labetalol on the newborn infant. Indian Pediatr, 29:1507- 1512, (1992).
19. TC Westfall and DP Westfall. Adrenergic agonists and antagonists. In: L Brunton, B Chabner and B Knollman, (eds.), Goodman and Gilman's The Pharmacological basis of Therapeutics, McGraw Hill, USA, 2011, pp. 328-329.
20. Mahmoud TZ, Bjornsson S, Calder AA., Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome. Eur J Obstet Gynecol Reprod Biol, 50(2):109-113, (1993).
21. Sibai BM, Gonzalez AR, Mabie WC, Moretti M., A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol, 70:323-327, (1987).
22. Rosenthal T, Oparil S., The effect of antihypertensive drugs on the fetus, J Hum Hypertens, 16:293-298, (2002).